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Abstract
Background: Dopamine (DA) is a major neurotransmitter playing an important role in the regulation of vertebrate
reproduction. We developed a novel method for the comparison of transcriptomic and proteomic data obtained from in
vivo experiments designed to study the neuroendocrine actions of DA.
Methods and Findings: Female goldfish were injected (i.p.) with DA agonists (D1-specific; SKF 38393, or D2-specific; LY
171555) and sacrificed after 5 h. Serum LH levels were reduced by 57% and 75% by SKF 38393 and LY 171555, respectively,
indicating that the treatments produced physiologically relevant responses in vivo. Bioinformatic strategies and a ray-finned
fish database were established for microarray and iTRAQ proteomic analysis of the hypothalamus, revealing a total of 3088
mRNAs and 42 proteins as being differentially regulated by the treatments. Twenty one proteins and mRNAs corresponding
to these proteins appeared on both lists. Many of the mRNAs and proteins affected by the treatments were grouped into
the Gene Ontology categorizations of protein complex, signal transduction, response to stimulus, and regulation of cellular
processes. There was a 57% and 14% directional agreement between the differentially-regulated mRNAs and proteins for
SKF 38393 and LY 171555, respectively.
Conclusions: The results demonstrate the applicability of advanced high-throughput genomic and proteomic analyses in an
amendable well-studied teleost model species whose genome has yet to be sequenced. We demonstrate that DA rapidly
regulates multiple hypothalamic pathways and processes that are also known to be involved in pathologies of the central
nervous system.
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Introduction
Cellular regulation of the transcriptome and proteome is
complex and the relationship between gene expression and protein
changes in vivo remain poorly understood in fishes [1]. We used the
adult female goldfish hypothalamus as a model system to
characterize the rapid transcriptomic and proteomic responses to
injection of dopamine (DA) receptor agonists. DA is widely
distributed in the vertebrate brain and is involved in motivation,
cognition, movement, and endocrine responses. DA exerts its
effects via the D1- and D2-classes of 7-transmembrane domain G-
protein-coupled receptors [2]. In fish, it is well understood that
DA, acting through the D1 and D2 receptor, stimulates growth
hormone release and inhibits luteinizing hormone (LH) release,
respectively [3]. Upon ligand binding, the D1-receptor stimulates
adenylate cyclase (AC) activity whereas the D2-receptor inhibits
AC activity [4], leading us to hypothesize that the specific receptor
agonists would lead to distinct transcriptomic and proteomic
profiles in the hypothalamus that reflect the mode of action of the
distinct receptors. Both D1 and D2 receptors also modulate
intracellular calcium levels [2]. We chose to characterize the
response to DA because it is a major central nervous system (CNS)
neurotransmitter with a fundamental inhibitory role in vertebrate
reproduction [3,5] and because of the importance of DA to
neurological disorders in humans [6,7,8].
Our model organism of choice was the goldfish, Carassius auratus
[3] because i) the role of DA as a central regulator of reproductive
processes is best-described in the goldfish; ii) a goldfish EST
project has been initiated; iii) transcriptomic analysis is possible
because of the development of a goldfish-carp cDNA microarray;
iv) it is a member of the Cyprinidae, one of the largest vertebrate
classes with over 2,400 species; and because v) goldfish are more
amenable to physiological and endocrine manipulations than
smaller fish such as zebrafish and medaka. On the other hand, the
paucity of genomic and proteomic data in goldfish, and in many
other important animal models other than laboratory rodents and
humans, presents a major challenge to evolutionary and
comparative physiologists.
To address this challenge, we developed a method for
transcriptomic and proteomic comparison and demonstrate its
utility for use on a model species with value to physiology and
endocrinology but having limited genomic information. We
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12338provide insights into the hypothalamic processes that are under the
regulation of DA in relation to its potent inhibitory actions on
pituitary luteinizing hormone (LH) release and thus vertebrate
reproductive function [3,5].
Materials and Methods
Ethics Statement
All procedures used were approved by the University of Ottawa
Protocol Review Committee (permit BL-234) and followed
standard Canadian Council on Animal Care guidelines on the
use of animals in research.
Experimental animals and design
Common adult female goldfish were purchased from a
commercial supplier (Aleong’s International Inc., Mississauga,
ON, Canada) and maintained at 18uC under a natural simulated
photoperiod on standard flaked goldfish food. Goldfish were
anaesthetized using 3-aminobenzoic acid ethylester (MS222) for all
handling, injection, and dissection procedures. Sexually mature,
pre-spawning (mid-May; GSI 4.561.3%) female goldfish (15–
40 g) were injected intraperitoneally with either SKF 38393 (D1
agonist; SKF; 1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-
7,8-diol; 40 mg/g) or LY 171555 (D2 agonist; LY; (-)-Quinpirole
hydrochloride; 2 mg/g) purchased from Tocris (Ballwin, MO,
USA). The experimental design and doses chosen were identical to
Otto et al. [9] who showed rapid effects on goldfish brain
somatostatin mRNAs. SKF was first dissolved in a minimal
amount (0.099% final concentration) of dimethylsulfoxide
(DMSO), and subsequently diluted with physiological fish saline
(0.6% NaCl). Concentrations of DMSO up to 0.1% do not affect
GH or LH levels [9]. LY was dissolved in saline. Control fish
received 2 i.p. injections (5 mL/g body weight) of saline or the
DMSO vehicle. SKF and LY-treated animals respectively received
a second injection of either saline or DMSO to control for the 2
different drug vehicles.
After 5 hours, blood was sampled (400–600 mL) by puncture of
the caudal vasculature via a 25-gauge needle attached to a 1-mL
syringe. The fish were sacrificed by spinal transection and
hypothalamic tissues were rapidly dissected and immediately
frozen on dry ice. Hypothalami were pooled (3/tube) to increase
RNA yield prior to RNA isolation. Serum was collected by
centrifuging the blood at 4,000 g at 4uC for 10 minutes. Serum
was stored at 280uC until used for the radioimmunoassay.
Radioimmunoassay for Luteinizing Hormone
The double antibody RIA protocol of Peter et al. [10] was used
to analyze serum LH levels, with minor modifications described by
Zhao et al. [11]. Data were tested for normality using SPSS v17.0
and determined not to be normally distributed. Data were
therefore log-transformed, determined to be normally distributed,
and a one-way ANOVA was performed to test for significant
differences (p,0.05).
RNA isolation and quality and cDNA synthesis
RNA was isolated with the TRIzol method (Invitrogen,
Burlington, ON, Canada) as per the manufacturer’s protocol.
Samples were treated with DNase on-column in an RNeasy Mini
kit (Qiagen, Mississauga, ON, Canada). RNA quantity was
evaluated using the NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientific). RNA quality was evaluated using the
2100 BioAnalyzer (Agilent); the RNA integrity number for all
samples was .8.4.
Microarray hybridizations
We previously described and validated the production and use
of our goldfish-carp cDNA microarray [12,13,14]. The array
contains 8832 cDNAs printed in duplicate and a detailed
description is published elsewhere [15]. Four microarray hybrid-
izations were performed for hypothalamic tissue for both D1 and
D2 agonists (total of 8 arrays) to screen for the effects of the
agonists in the neuroendocrine brain. Three separate pools of
RNA from treated fish were hybridized to the microarrays, and a
fourth hybridization was a replicate dye-reversal of one of the
three RNA pooled samples. Hybridizations were carried out
relative to a common pool of control samples (,30 control fish) for
each tissue, which decreases technical variation as only one
reference is utilized while maintaining biological variation of the
treatment samples [16]. All cDNA synthesis, labeling, and
hybridizations were performed using the Genisphere 3DNA Array
900MPX kit according to the manufacturer’s protocol (Geni-
sphere, Hatfield, PA). Hybridizations and scanning protocols were
described previously [12,13,14]. Briefly, microarrays were scanned
at full-speed 10-mm resolution with the ScanArray 5000 XL system
(Packard Biosciences/PerkinElmer, Woodbridge, ON, Canada)
using both red and blue lasers. Images were obtained with
ScanArray Express software using automatic calibration sensitivity
varying photomultiplier (PMT) gain (PMT starting at 65% for Cy5
and 70% for Cy3) with fixed laser power at 80% and the target
intensity set for 90%. Microarray images were analyzed with
QuantArray (Packard Biosciences/Perkin Elmer), and raw signal
intensity values were obtained for duplicate spots of genes. Raw
intensity values for all microarray data and microarray platform
information have been deposited in the NCBI Gene Expression
Omnibus database (Series accession no. GSE14607 (SKF) and
GSE14610 (LY)) under MIAME compliance. Generalized Pro-
crustes Analysis [17] was used for normalization of the array data
and the Significance Analysis of Microarrays (SAM) method [18]
was used to identify significantly regulated transcripts.
Protein quantification and database search using iTRAQ
labeling
The iTRAQ labelling protocol has been previously described in
detail in Martyniuk et al. [19]. Briefly, approximately 20 mg of
hypothalamic tissue was collected and mechanically disrupted and
homogenized in 500 mL RIPA (25 mM Tris-HCl pH 7.6,
150 mM NaCl, 1% nonyl phenoxylpolyethoxylethanol-40, 1%
sodium deoxycholate and 0.1% SDS) (Pierce, Thermo Fisher
Scientific Inc. Rockford, IL., USA) and proteins were precipitated
in 3 mL of acetone. After removal of acetone, proteins were
resuspended in iTRAQ dissolution buffer (Applied Biosystems Inc,
Foster City, CA) and vortexed. Using 100 mg total protein/sample,
we performed three independent iTRAQ labeling experiments
following the manufacturer’s protocol (Applied Biosystems Inc,).
For proteomics analysis, each labeling reaction consisted of a
single hypothalamus for control (label 114), LY 171555 (D2
agonist; label 115), and SKF 38393 (D1 agonist; label 117) (total
n=9 samples used; n=3 per iTRAQ experiment). After labelling
the independent samples for each iTRAQ experiment, they were
mixed together and processed through desalting via a macrospin
column Vydac Silica C18 (The Nest Group Inc, Southboro, MA),
each and then subjected to off-line SCX fractionation on a
polysulfoethylA column. The following fractions were collected for
each of the three iTRAQ experiments: 7 (iTRAQ 1), 11 (iTRAQ
2), and 10 (iTRAQ 3). LC-MS/MS analysis on each of these
fractions was performed on a hybrid quadrupole-TOF mass
spectrometer QSTAR XL (Applied Biosystems).
Dopamine on the Fish Brain
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(details in [19] using MS/MS data interpretation algorithms
within Protein Pilot
TM (Paragon
TM algorithm, v 2.0, Applied
Biosystems). The Paragon algorithm searched iTRAQ 4-plex
samples as variable modifications with methyl methanethiosulfo-
nate as a fixed modification [20]. The Protein Pilot
TM algorithm
was selected to search automatically for biological modifications
such as homocysteines. The confidence level for protein
identification was set up to 1.3 (95%), which is the default setting
for the detected protein threshold in a Paragon
TM method.
Proteomics System Performance Evaluation Pipeline (ProteomicS
PEP, Applied Biosystems) in Protein Pilot
TM was used to create a
reversed ray-finned fish database to calculate a false discovery rate
(FDR). When searching the ProteomicS PEP reverse database,
621 proteins were identified with an FDR of 1%, thus there is high
confidence (.99%) in the peptide-protein assignments in this
study. Differential expression ratios for proteins were obtained
from Protein Pilot
TM which calculates protein ratios using only
ratios from the spectra that are distinct to each protein, excluding
the shared peptides of protein isoforms. Peptides with low spectral
counts were also excluded from the calculation of averages by
setting the intensity threshold for the sum of the signal-to-noise
ratio for all the peak pairs at .9. A protein with three high quality
peptide spectra used in quantitation is considered to be a confident
quantitation. However, we also report proteins in which two
spectra were used in the quantitation for comparison. To calculate
differential expression ratios, all identified spectra from a protein
were used to obtain an average protein ratio relative to the control
label (i.e. fold change). The p-value was calculated using the
confidence intervals from the error factor generated in Protein
Pilot
TM.
Bioinformatics
Protein sequences from proteins identified by iTRAQ analysis
as differentially expressed were downloaded from NCBI using
extracted GI numbers with a BioPerl script (Fig. S1). The protein
sequences were converted into a searchable database using
formatdb. All of the nucleotide sequences identified as being
differentially expressed (q,5%) from the agonist experiment were
compared (blast-2.2.19) against the above database through
Blast2GO [21]. A graphical depiction of the workflow is presented
in Fig. S2.
Results and Discussion
Our in vivo treatments both confirmed previous research and
provided new hormone-regulatory data. Circulating serum LH
was rapidly suppressed following DA agonist injections (Fig. 1). It
is well known that DA, via the pituitary D2 receptor, is the
primary inhibitor of LH release in goldfish and numerous other
teleosts [5,22,23,24,25,26,27,28,29,30,31]. Here we corroborate
these findings and show that LY 171555 (LY) rapidly reduced
circulating LH levels to 25% of control. Unexpectantly, we found
that the DA-D1 agonist SKF 38393 (SKF) decreased LH by 43%,
which is a novel finding for DA regulation of in vivo LH release in
fish. It is known that activation of D1-receptors inhibits the release
of gonadotropin-releasing hormone (GnRH) [32], and thus may
have an impact on GnRH-stimulated LH release. We have
subsequently begun further investigation the involvement of D1
receptors in LH release [33]. Most relevant here, however, is that
our DA agonist treatments produced physiologically relevant
changes in circulating hormone levels, so we proceeded to analyse
transcriptomic and proteomic responses in the hypothalamus, the
central integrator of external and endogenous signals. Compared
to other vertebrates, fish have very high hypothalamic levels of DA
due to a duplicated tyrosine hydroxylase gene (th2) [34].
Importantly, the goldfish posterior tuberculum (TPp; or nucleus
posterior tuberis; NPT), a region with intense immunostaining for
th1 but lacking immunostaining for dopamine b-hydroxylase, lies
within the hypothalamus [35,36,37]. Thus, we proceeded to
determine the effects of DA agonist injection on hypothalamic
function.
Transcripts identified in the goldfish hypothalamus as
differentially regulated by dopamine agonists
In total, 3088 ESTs were identified as being statistically (q,5%)
significantly differentially expressed following either D1-o rD 2-
receptor stimulation in the hypothalamus. Many of these are as yet
uncharacterized (Fig. S3). Of the 1042 ESTs that are annotated,
gene ontology (GO) classifications (Fig. S4) revealed that a large
percentage are involved in the regulation of biological process
(13%), signal transduction (10%) and nucleotide binding (19%).
Furthermore, 29% of the cDNAs were localized to GO Cellular
Component category of the protein complex, suggesting that many
of the proteins are involved in macromolecular complexes,
reflecting the receptor targets for the agonists.
A recent review by Altar et al. [38] summarized targets for the
identification of CNS diseases using transcriptional profiling of
human post-mortem brain, animal models, and cell culture
studies. Many of the transcriptional targets reported by Altar
et al. [38] were also differentially regulated by DA in the goldfish
hypothalamus. For example, mRNAs for glutamic acid decarbox-
ylase (GAD) 1, microtubule-associated protein tau, serpin A,
malate dehydrogenase, regulator of G-protein signaling, transfer-
rin, s100 calcium binding protein, glutathione-S-transferase,
calmodulin, a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
(AMPA) receptors, glial fibrillary acidic protein, N-methyl-D-
aspartic acid (NMDA) receptor 1, glutamate transporter, calbin-
Figure 1. Serum LH concentration following DA agonist
injections. Mean (6 SEM) serum LH concentration in control and
injected (40 ug/g SKF 38393 or 2 ug/g LY 171555) female goldfish
(n=23226 each). Results presented are the average of 2 identical but
independent experiments that showed similar results. Data was log-
transformed to approximate normality and a one-way ANOVA was
performed in SPSS v16 with significance considered at p,0.05, followed
by Tukey’s HSD multiple comparisons as data was homoscedastic.
* signifies p,0.001 relative to control.
doi:10.1371/journal.pone.0012338.g001
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c, glutamine synthetase, and DA receptors and a DA transporter
were all identified as being differentially regulated (Table S1) and
are linked to CNS diseases such as Alzheimer’s disease (AD),
Parkinson’s disease (PD), and schizophrenia, as well as brain aging
[38,39,40].
Injection of SKF modulated hypothalamic mRNA levels for key
transcripts in the glutamate and c-aminobutyric acid (GABA)
pathways (Table S1) in goldfish [3,41]. In goldfish, GABA has a
prominent stimulatory action on LH release by enhancing GnRH
release and by reducing DA turnover in the hypothalamus [42,43].
Our working hypothesis is that GABAergic systems transduce
environmental (e.g. temperature) and endocrine (e.g. sex steroid)
signals by rapid effects on both GnRH and DA to enhance LH
release during seasonal gonadal redevelopment [41,44,45]. Results
from the current study support this hypothesis.
Protein identification in the goldfish hypothalamus
For this experiment, we repeated DA agonist treatments on the
same date the following year using an identical design. Serum LH
was similarly decreased in both years and the data presented were
combined (Fig. 1). The hypothalami from this experiment were
subjected to iTRAQ proteomic analysis.
There were 621 proteins identified in this study using a ray-
finned fish database previously constructed [19] (Table S2). The
total number of peptide spectra detected was 8569, representing
4779 distinct peptides that are listed in Dataset S1. Of the peptides
identified, 59.7% could be assigned to a protein, leaving
approximately 40% of the spectra unidentified by homology
searches against other ray-finned fishes.
Of the 621 identifiable proteins, 42 were determined as being
significantly (p,0.05) differentially regulated by either SKF or LY
(Fig. 2). The protein dataset (for both D1 and D2 results
combined) was analyzed using Blast2GO and binned into their
corresponding GO terms (Fig. 3). Similarly to the mRNAs affected
in this study, many of the proteins affected by the treatments are
localized to the GO Cellular Component of the protein complex
and are involved in a wide variety of biological processes,
including signal transduction, response to stimulus, and both
positive and negative regulation of cellular process. Of interest
here are the proteins in the GO category of Biological Processes as
related to neurotransmitter secretion and calcium ion transport.
Calcium/calmodulin-dependent kinase II a subunit (CaMKIIa),
calbindin 2, neuronal calcium-binding protein 2, plasma mem-
brane calcium ATPase 4, and calmodulin (CaM) proteins were
significantly affected by at least 1 of the DA agonists (Table 1).
Calmodulin protein was decreased by LY, but not SKF,
suggesting that in hypothalamic CaM expression is D2-, rather
than D1-, receptor-regulated. Previous research demonstrated that
CaM is expressed in the hypothalamus and the pituitary of
goldfish and LY, but not SKF, decreased CaM mRNA levels in
goldfish pituitary cells [46]. Together the data indicate CaM is
under the regulation of the D2 receptor in the goldfish
hypothalamo-pituitary system. We have also identified CaM as
being important and regulated in the hypothalamus using a meta-
type analysis of data from multiple goldfish microarray exper-
iments performed across the seasonal breeding cycle. The mRNA
for CaM was relatively highly expressed in the hypothalamus of
sexually mature females in May, compared to both sexually
regressed (August) or recrudescing animals in the gonadal
redevelopment phase (December) [47]. This information, coupled
with the changes in mRNA and protein levels of CaM (this study),
suggests that CaM may be important for DA inhibition on LH
release and thus inhibitory control of reproduction.
CaMKIIa protein levels, whose transcript levels follow the same
seasonal profile as CaM (high in May, low in August and
December) [47], were increased in both D1- and D2-agonist
treated fish suggesting that, as for CaM, CaMKIIa may be
Figure 2. Venn Diagram summarizing the number of cDNAs and proteins found in the hypothalamus of female goldfish. The
comparison of those regulated by DA was limited to cDNAs (q,5%) and proteins (FDR-adj p,0.05) identified as being statistically significant.
Duplicate cDNAs were removed; cDNAs and proteins were counted once regardless if they were regulated by both agonists. The complete listing of
cDNAs and proteins are listed in Tables S1 and S2, respectively.
doi:10.1371/journal.pone.0012338.g002
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PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e12338Figure 3. GO categorization of differentially expressed proteins identified in the current study. Proteins identified by iTRAQ (42; p,0.05)
were binned into multilevel GO categorizations with a sequence cut-off of 3. Both treatments (D1 and D2) and both directions are included in this
analysis but are counted only once if the protein is common to both treatments.
doi:10.1371/journal.pone.0012338.g003
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Protein Corresponding mRNA
Accession Name Fold Change Accession Blast2GO-annotated mRNA (NCBI) Fold Change
SKF LY SKF LY
AAW82445 14 kDa apolipoprotein* 21.3 CA967592 14 kda apolipoprotein 21.6
AAW82445 14 kDa apolipoprotein* 21.5 CF662502 14 kda apolipoprotein 1.9
CAG00145 25 kDa synaptosomal-associated
protein
21.5 CA969142 synaptosomal-associated
protein 25
1.4
NP_956213 adaptor-related protein complex 2,
beta 1 subunit
1.3
AAH83251 Atp2b4 protein 1.4
AAZ38450 beta thymosin-like protein 21.3
AAF79948 brain-type fatty-acid binding protein;
B-Fabp
21.4
CAK04737 calbindin 2, like 21.2
NP_001017741 calcium/calmodulin-dependent protein
kinase II alpha
2.3 1.8
Q71UH6 Calmodulin 21.2 CA969795 calmodulin variant 1 1.4
CAF92971 Creatine kinase, brain 21.4
NP_942096 creatine kinase, mitochondrial 1 1.2
CAK10905 cytochrome c oxidase subunit IV
isoform 1
1.2
AAV52802 glutamine synthetase 1.4 21.3 FG393017 glutamine synthetase 1.9
ABD67511 glutathione S-transferase rho 21.3 21.2 CA964231 glutathione S-transferase rho 21.6
AAV52803 glyceraldehyde-3-phosphate
dehydrogenase
21.4 DY231775 GAPDH 1.6
AAA21578 kainate receptor a subunit 1.8 1.3 FG392717 kainate receptor a subunit 1.4
AAH63955 Krt5 protein 2.6
AAM21708 liver-basic fatty acid binding
protein*
3.6 CA968596 fatty acid binding protein liver
basic
1.4
AAM21708 liver-basic fatty acid binding
protein*
8.6 CA970443 fatty acid binding protein
liver basic
21.5
NP_956241 malate dehydrogenase 1a, NAD
(soluble)
1.2 CA964750 malate dehydrogenase nad 2.0 1.3
ABC69306 myoglobin isoform 2 21.4 CA968088 myoglobin 1.4
NP_958898 N-ethylmaleimide-sensitive factor 1.3 FG392958 n-ethylmaleimide-sensitive factor 1.4
CAN88379 novel protein sim to vert EF hand
calcium binding protein 2 (EFCBP2)
21.1
CAK05381 parvalbumin 21.1 CA969705 parvalbumin 1.5
ABF57553 Pi-class glutathione S-transferase 21.7 21.6
BAA78376 polypeptide elongation factor
1 alpha
1.3 CA967511 eukaryotic translation elongation
factor 1 alpha 1
21.8
XP_001340376 PREDICTED: myelin basic protein
isoform 3
23.9 CA967910 myelin basic protein 2.0
CAF98839 PREDICTED: similar to germinal
histone H4 gene
21.1
XP_001338014 PREDICTED: similar to microtubule-
associated protein 1 A
1.4
XP_696230 PREDICTED: similar to microtubule-
associated protein tau
21.1 CA967834 microtubule-associated protein tau 1.9
XP_001335551 PREDICTED: similar to Myelin basic
protein
21.5 21.5
XP_691535 PREDICTED: similar to Nj-synaphin 2 22.2
CAF95822 Putative histone cluster 1, H2bb 21.6 21.5
AAG14350 putative oncoprotein nm23 21.3 CA964203 non-metastatic cells 2, protein (NM23B) 21.6
AAI14255 short chain dehydrogenase/reductase 21.9 21.5 CA968680 dehydrogenase reductase sdr family
member 12
1.3
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cAMP response binding element (CREB) protein, thereby
inhibiting its function [48], which may lead to downstream
transcriptional repression of genes involved in reproduction.
Furthermore, CaMKII positively regulates the D2 receptor
promoter in rats [49], suggestive of a feedback mechanism of
DAergic action.
We observed a decrease in hypothalamic Apo-14 protein
expression with both D1- and D2- receptor agonists. Apo-14
appears to be specific to teleost fish [50], although a recent
phylogenetic analysis revealed that Apo-14 is the homologue to
mammalian ApoA-II [51]. Apo-14 is mainly expressed in liver and
brain of adult orange-spotted groupers and has been suggested to
play a role in neuronal growth and repair [52], similar to ApoE
[53]. Vitale and Carbajal [54] demonstrated that DA induces
substantial cytoskeletal remodelling in rat lactotrophs in vitro. The
decreases in Apo-14, stathmin 1, microtubule-associated protein
tau, along with an increase in microtubule-associated protein 1A
and spectrin alpha 2 (Table 1) suggests that DA may also have
remodelling effects on the cytoskeleton of cells in the goldfish
hypothalamus. The likely high energetic demands for such
remodelling is supported by the observed increase of mitochon-
drial creatine kinase, cytochrome c oxidase subunit IV, and malate
dehydrogenase protein levels (Table 1).
A comparison of the differentially expressed
transcriptome to the differentially expressed proteome in
response to DA agonists
The protein dataset was further compared to the microarray
dataset by extracting the GI numbers from the protein results. A
BioPerl script (Fig. S1) was used to obtain the corresponding
amino acid sequences from GenBank, which were converted into a
database that can be queried using the BLAST algorithm. This
step was necessary in order to obtain the longest possible protein
sequence data for the comparison. The nucleotide sequences
represented on the microarray were compared (BLASTx) to this
differentially-expressed protein database. The results (Table 1)
show directional correlation for some mRNAs and proteins (for
example, kainate receptor a subunit and 14 kDa apolipoprotein
for D1 and liver-basic fatty acid binding protein for D2), while
others are inversely correlated (for example, stathmin 1/oncopro-
tein 18 with either agonist). The mRNAs and their respective
proteins exhibiting discordant directional change following agonist
treatments nevertheless indicate that particular pathways and
processes are DA-regulated. Differences in the direction of change
between transcript and protein is likely related to our single
sampling time-point, as the time-series relationship between
changes in transcript versus protein in vivo are poorly understood
in fish [1]. Furthermore, the regulatory mechanisms of the genome
and proteome are complex and both turnover and stability of
mRNA levels are important for translation of mRNA into protein
[55]. For example, if the mRNA is decreased, but the protein is
increased, it is possible that the mRNA has already begun to be
degraded. Conversely, if the mRNA is increased, but the protein is
decreased, there may be regulation of translational pathways, or
increased protein degradation leading to induced transcription.
These are good candidates for temporal (i.e., 1–3 hr time-course),
biochemical (with/without cycloheximide) and pulse-chase anal-
ysis to better understand the differences. The interest here,
however, lies with those mRNAs and proteins that share a
common direction. In the D1-agonist-treated fish, 8 out of the 14
common mRNAs/proteins (57%) share a common directional
change, whereas only 1 out of 7 of the common mRNAs/proteins
(14%) for the D2-agonist-treated fish that change in parallel
(Table 1). These results are comparable to what has been shown in
the rat colon mucosa in vivo where only 16% direction identity
between the transcriptome and the proteome was found [56].
Furthermore, that study included the development of a TRIzolH-
Protein Corresponding mRNA
Accession Name Fold Change Accession Blast2GO-annotated mRNA (NCBI) Fold Change
SKF LY SKF LY
NP_001091958 spectrin alpha 2 1.3 FG392760 spectrin alpha 2 1.4
NP_001017850 stathmin 1/oncoprotein 18* 21.3 CA969799 stathmin 1 oncoprotein 18 variant 8 1.4
NP_001017850 stathmin 1/oncoprotein 18* 21.5 CA966170 stathmin 1 oncoprotein 18 variant 8 1.5
NP_001018488 synuclein, gamma b (breast cancer-
specific protein 1)
21.5
AAM90972 transferrin variant A1 1.5 CA968595 transferrin variant c 1.9
AAM90973 transferrin variant B1 21.9
NP_705954 triosephosphate isomerase 1b 21.3 21.2 CA968504 triosephosphate isomerase 1b 1.8
NP_997770 tyrosine 3-/tryptophan 5-
monooxygenase activation protein,
epsilon polypeptide
1.1
AAQ94569 ubiquitin C 21.3
Proteins were determined by iTRAQ as being significantly (FDR-adj p,0.05) differentially regulated in the hypothalamus of female goldfish treated with either SKF
38393 (SKF) or LY 171555 (LY) agonists. This table also show the cDNAs corresponding to the proteins identified by microarray analysis as significantly (q,5%) affected
by the same treatments. Negative values indicate a decrease relative to control. Absent values indicate either that no significant change was detected, or, in the case of
the mRNAs, that the corresponding cDNA was not present on the array. mRNAs were annotated using Blast2GO’s Blast Descriptor Annotator with default values except
the Blast ExpectValue was changed from 1.0E-3 to 1.0E-5. Following the Mapping step, the Annotation Configuration E-Value-Hit-Filter was changed from 1.0E-6
(default) to 1.0E-8 to increase the likelihood of proper GO annotation. Duplicates were assessed on the basis of sequence comparison and removed if a similar
expression was observed. In the case where different expression profiles were seen (*), both ESTs were included, as it is possible that the sequences correspond to
separate genes.
doi:10.1371/journal.pone.0012338.t001
Table 1. Cont.
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from the same sample, which should reduce disagreements in the
gene-protein correlation. Our results show that a comparable
directional correlation from independent animals and experiments
can also be achieved. This is significant, as it shows that the
technique is applicable to a species with limited genomic
information.
While some of the proteins identified as differentially expressed
had corresponding changes in mRNA levels, many other cDNAs
representing coding sequences for other proteins that were
regulated were not printed on our array. For example, the Nj-
synaphin 1 (also known as complexin 1) protein was identified as
being down-regulated 2.2-fold in response to the D2-agonist
(Table 1) but the complexin cDNA was not on the array.
Interestingly, in addition to complexin 1, proteins for both N-
ethylmaleimide-sensitive factor (NSF) and soluble NSF attachment
protein- (SNAP-) 25, all of which are major players in the
exocytosis of neurosecretory vesicles [57], were affected by the D2
agonist. Current evidence [58,59] indicates that complexin holds
the vesicle in a ‘‘ready-to-release’’ state near the membrane, while
preventing the spontaneous zippering of the t- and v-SNAREs and
thus spontaneous fusion of the vesicle to the membrane. Upon
introduction of Ca
2+, which binds to synaptotagmin, complexin is
removed and the membranes fuse, resulting in exocytosis. Since
complexin expression is decreased, our results suggest that DA is
stimulating some aspects of exocytosis in the hypothalamus via the
D2 receptor. However, we found that SNAP-25 protein levels
were reduced by the D2-agonist, suggesting that DA may also be
inhibiting some of the exocytotic machinery. Perhaps this is a
homeostatic mechanism to prevent or reduce the release of
neurotransmitters and neurohormones in response to acute
DAergic overstimulation.
NSF protein levels were increased in response to the D2 agonist.
NSF transcript levels were initially found to be decreased in
schizophrenic patients [60] but this was not observed in
subsequent studies [38]. Similarly to CaM, the meta-analysis by
Zhang et al. [47] identified NSF transcripts as being relatively
highly expressed in May when goldfish are sexually mature. This
information, coupled with the D1-mediated increase in NSF
mRNA or D2-mediated increase in NSF protein found in this
study, suggest that the DAergic inhibition of LH release involves
hypothalamic NSF-dependent mechanisms.
Glutamine synthetase (GlnS) mRNA and protein levels were
increased in response to SKF (Table 1). GlnS converts glutamate
(Glu) to glutamine (Gln) and thus may limit the available pool of
Glu, which is an excitatory neurotransmitter stimulating LH
release in vertebrates including goldfish [41]. Increased GlnS
could also potentially limit the Glu available to be converted by
GAD to GABA. The observation in this study that GlnS is
increased in response to a D1-specific agonist supports this
hypothesis and suggests a possible mechanism of decreased LH
secretion via D1-receptor stimulation. In contrast to SKF, GlnS
protein levels were decreased in response to LY, with no
observable effect on GlnS mRNA levels (Table 1). This differential
response to the 2 DA agonists is likely due to responses in
adenylate cyclase (AC) [61] since both receptors act via this second
messenger system [2]. Generally, D1-class receptors, through
interactions with Gs proteins, stimulate AC, whereas D2-class
receptors, through interactions with Gi proteins, inhibit AC [2].
Glutamate can also be converted to glutathione-conjugated
products through multiple enzymatic steps with the final step
being mediated by glutathione S-transferase (GST). GST rho and
Pi-class GST (GSTp) protein levels were reduced by both DA
receptor agonists in the current study. It is not clear at this time
whether the reduced GST protein levels are the result of DA
receptor stimulation or rather a consequence of reduced substrate
flux through that pathway initiated by limited pool of available
Glu, as discussed above. However, it is likely not the latter case, as
GST protein levels were reduced by both DA agonists, but GlnS
protein levels were affected in different directions.
Glutathione is an antioxidant and helps to protect cells against
damage from reactive oxygen species [62]. DA has been shown to
induce apoptotic cell death in a CNS-derived catecholaminergic
cell line [63] and Ishisaki et al. [64] identified GSTp as a candidate
that protects against cell death in PC12 cells. Furthermore,
inhibition of GSTp increased DAergic neuronal cell death in
Swiss-Webster rats treated with MPTP [65], a specific DAergic
neurotoxin. Interestingly, Shi et al. [66] recently reported increased
GSTp protein levels in synaptosomal fractions from the frontal
cortices of patients with pathologically-verified PD and suggest that
GSTpmay be importantinthe progression ofthedisease.In studies
with GSTp-null mice, Henderson et al. [67] demonstrated that
GSTp may enhance the hepatotoxicity of acetaminophen. While
speculative, the observation of decreased GSTp protein levels in
response to either D1- or D2-specific agonists in the current study
suggests that DA may also modulate hypothalamic neuronal cell
death in fish. This hypothesis is further supported by predominant
increases observed in mRNAs for multiple heat shock proteins,
ubiquitination enzymes, and proteasomal subunits by both D1- and
D2-specific agonists (Table S1).
Several other proteins identified as differentially regulated by
DA in goldfish have also been reported to be involved in human
neurological disorders. For example, malate dehydrogenase, CaM,
transferrin, tyrosine-3-monooxygenase/tryptophan-3-monooxy-
genase activation protein epsilon (YWHAE), microtubule-associ-
ated protein tau and beta-synuclein are among proteins identified
that are known to be involved in neurodegenerative and/or
psychiatric diseases [38].
There is a discrepancy between the number of mRNAs and
proteins that were identified as differentially regulated that must
be addressed. Many mRNAs for abundant ribosomal proteins
were induced, and some of the corresponding proteins were
detected, but did not change. This is not unexpected since it
would be difficult to observe a change in protein concentration
above the background of these proteins found in ribosomes in
eukaryotic tissues. This is similar to what has been demonstrated
in yeast [68]. However, for other mRNAs/proteins, there may be
other factors restricting concordant changes. For example, our
use of a ‘‘snapshot’’ time frame study is a likely limitation that
does not allow us to take into account differences in mRNA
versus protein half-lives. Furthermore, steady-state mRNA levels
for many ESTs were increased by 5 h following agonist
treatments, but the translational machinery may require
additional time to efficiently produce the corresponding proteins.
Importantly, despite the recognized limitations we outline, the
level of concordance in the mRNA and protein changes in the
goldfish brain are well within the ranges seen with better
characterized vertebrate systems [56,69,70]. Future studies
aimed at examining the temporal correlation between the
hypothalamic transcriptome and proteome should reveal further
relationships and critical pathways regulated by the neurotrans-
mitter DA, and provide insights into the neural processes
governing reproduction.
In conclusion, we have demonstrated the applicability of
advanced high-through genomic and proteomic analyses in an
amenable well-studied teleost model species whose genome has yet
to be sequenced. Furthermore, we demonstrate the first evidence
of D1-receptor involvement in the inhibition of LH release and
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stimulatory neurotransmitters, namely glutamate and/or GABA.
Refinement of the bioinformatic methods for time-course analysis
should further reveal the importance of DA in regulating
hypothalamic function.
Supporting Information
Figure S1 Perl script used to extract amino sequences from
GenBank.
Found at: doi:10.1371/journal.pone.0012338.s001 (0.24 MB TIF)
Figure S2 Information workflow diagram for comparing
mRNAs to proteins.
Found at: doi:10.1371/journal.pone.0012338.s002 (0.42 MB TIF)
Figure S3 Number of ESTs identified by microarray analysis as
being statistically (q,5%) differentially regulated by dopamine
agonists in the hypothalamus of female goldfish 5 h post-i.p.-
injection. The data distribution is shown as output from
Blast2GO. Duplicates were removed. Overlapping ESTs (i.e.
ESTs regulated by more than 1 agonist) are indicated as ‘‘Shared
between…’’.
Found at: doi:10.1371/journal.pone.0012338.s003 (0.44 MB TIF)
Figure S4 Multilevel Gene Ontology categorization of the 1042
annotated ESTs into a) Biological Process, b) Molecular Function,
and c) Cellular Component. Annotations were first converted to
GO-Slim annotations (goslim_generic.obo) and the multilevel
chart was constructed using a sequence convergence cutoff of 30 to
reduce the complexity of the chart. Both agonists and both up- and
down-regulated genes (q,5%) are included in this analysis.
Found at: doi:10.1371/journal.pone.0012338.s004 (3.21 MB TIF)
Table S1 Complete list of cDNAs identified as significantly
(q,5%) differentially regulated by SKF 38393 (SKF) or LY
171555 (LY). Negative fold changes indicate a decrease in the
mRNA level.
Found at: doi:10.1371/journal.pone.0012338.s005 (1.07 MB
DOC)
Table S2 All goldfish proteins identified in the hypothalamus in
this study. Proteins in which a single peptide was used in
identification are also presented in this table. % Cov is the amount
of amino acid coverage (%) by peptides. Ratios (e.g. 115:114) are
each treatment (tag 115 or 117) divided by control (tag 114) to
obtain relative fold change. Pval is the p-value after all peptides for
a protein were used for quantitation. The Error Factor (EF)
expresses the 95% uncertainty range for a reported ratio. The true
protein ratio is expected to be found between the (reported
ratio)*(EF) and the (reported ratio)/(EF) 95% of the time. Peptides
used in quantification also included all peptides with post-
translational modifications and all charge states (Dataset S1).
Peptides that do not have a Ratio or P-value were not quantified
because 1) peptide signal was too low; 2) peptide did not meet
standard for quantitation; or 3) peptide belonged to more than one
unique protein.
Found at: doi:10.1371/journal.pone.0012338.s006 (0.75 MB
DOC)
Dataset S1 The total number of peptide spectra detected in the
goldfish hypothalamus
Found at: doi:10.1371/journal.pone.0012338.s007 (2.92 MB
XLS)
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